A Lifecourse Map of Diseases in China

Sponsor

Shandong University (Other)

Overall Status

Recruiting

CT.gov ID

NCT05612230

Collaborator

National Health Medical Data (North Center) (Other)

40,000,000

Enrollment

Location

Anticipated Duration (Months)

1667808.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group.

Condition or Disease	Intervention/Treatment	Phase
Common Diseases Rare Diseases	Other: Data analysis

Detailed Description

Studying the distribution of various diseases in specific populations can help explore the causes of diseases, elucidate the distribution patterns, and develop preventive and control measures. Based on an overall assessment of prevalence, the combination of relevant results with age at diagnosis for multiple diseases is important for further understanding of the distribution of diseases at the population level. Therefore, this study aims to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group, thus providing a reference for more effective prevention, diagnosis and treatment of diseases.

Study Design

Study Type:

Observational

Anticipated Enrollment :

40000000 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

A Lifecourse Map of Common Diseases and Rare Diseases in China

Actual Study Start Date :

Aug 1, 2022

Anticipated Primary Completion Date :

Jul 31, 2023

Anticipated Study Completion Date :

Jul 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Hospitalized patients The diseases were included based on the results of the preliminary data exploration and standardization according to ICD-10.	Other: Data analysis Data analysis is based on a single database from the National Health Medical Data (North Center).

Arm

Intervention/Treatment

Hospitalized patients

The diseases were included based on the results of the preliminary data exploration and standardization according to ICD-10.

Other: Data analysis

Data analysis is based on a single database from the National Health Medical Data (North Center).

Outcome Measures

Primary Outcome Measures

age-specific prevalence rate [between January 1, 2017 and December 31, 2021]
Age-specific prevalence rate stratified by sex were calculated by dividing the number of incident cases with a current disease by the total number of people in the study population during that time period.
sex-specific prevalence rate [between January 1, 2017 and December 31, 2021]
Sex-specific prevalence rate stratified by age for 10-year bands were calculated by dividing the number of incident cases with a current disease by the total number of people in the study population during that time period.

Secondary Outcome Measures

total cost of hospitalization [between January 1, 2017 and December 31, 2021]
Total cost of hospitalization and deductibles for the total population and for each age group of diseases are described by mean (SD) values.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All inpatients within the period of January 1, 2017 to December 31, 2021.
Patients with discharge diagnosis.
Patients with accurate gender and age records.

Exclusion Criteria:

Morbidity and mortality due to external causes, i.e. injuries, poisonings and other adverse events due to external environment and accidents.
Pregnancy-related conditions.
Symptoms, signs, abnormal clinical and laboratory findings.
Traditional Chinese Medicine diagnosis records.
Patients with incorrect or missing disease codes.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Shandong University	Jinan	Shandong	China	250012

Sponsors and Collaborators

Shandong University
National Health Medical Data (North Center)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Wei Zhao, Head of department of clinical pharmacy and pharmacology, Shandong University

ClinicalTrials.gov Identifier:

NCT05612230

Other Study ID Numbers:

2022-DISEASE

First Posted:

Nov 10, 2022

Last Update Posted:

Nov 10, 2022

Last Verified:

Nov 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Rare Diseases

Study Results

No Results Posted as of Nov 10, 2022